Identifying the patient journey and treatment lines patterns in metastatic pancreatic cancer

Data from patients using the Belong PPN was able to provide insights into the treatment journeys of MPC patients in Israel, the four firstline treatment prevalence and the following lines of treatment. Continuous evaluation of RWE and PRO from the Belong PPN would allow comparative effectiveness research of cancer treatments and lead to improved evidence-based … Continued

Read More

Mapping PD-1 inhibitors’ side effects using patient reported outcomes (PRO)

Data from the Belong PPN successfully captured the spectrum of PD-1 inhibitors’ reported AEs. Analyzing PRO of post approval treatments could provide deeper understanding of treatment patterns, expose limiting AE that bear implications on cost of treatment, indicate patients’ quality of life (QOL), improve management recommendations and provide a comprehensive outlook of patients’ outcomes. Click … Continued

Read More

Belong implementation results at the gynecological cancer care in JGH

See the latest study that was conducted by McGill university and the Jewish general hospital in Toronto, Canada, using the Belong.Life platform. These are the main results of the study. 84% agreed or strongly agreed that Belong helped them feel less alone 80% agreed or strongly agreed that Belong helped them feel better prepared for medical consultations … Continued

Read More

2018 Belong’s fatigue survey

New Cancer Patient Survey Shows Emotional Impact of Illness-Related Fatigue Greater than Physical Effect Fatigue is the Strongest Influence of Compliance, Therapeutic Selection and Continuation of Treatment Belong Cancer Patient Social Network Asks Users about Common Factors Connecting Fatigue and Cancer New York, NY – May 9, 2018 – Belong.Life, the world’s fastest-growing and largest cancer … Continued

Read More